Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia

Autor: Nadine Kutsch, Christian Pallasch, Eugen Tausch, Volkmar Böhme, Matthias Ritgen, Rüdiger Liersch, Alexander Wacker, Georg Jacobs, Ralf Ulrich Trappe, Peter Dreger, Kirsten Fischer, Anna-Maria Fink, Stephan Stilgenbauer, Shuyan Zhai, Biao Li, Juliane M. Jürgensmeier, Nishanthan Rajakumaraswamy, Pankaj Bhargava, Michael Hallek, Barbara F. Eichhorst

Publikováno v: HemaSphere, Vol 6, Iss 4, p e692 (2022)

Externí odkaz: https://doaj.org/article/cc1dd22b903a4e9bb9d8ee19e48800b6

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Autor: John F. Seymour, Thomas J. Kipps, Barbara F. Eichhorst, James D’Rozario, Carolyn J. Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Brenda Chyla, Anesh Panchal, Tong Lu, Jenny Q. Wu, Yanwen Jiang, Marcus Lefebure, Michelle Boyer, Arnon P. Kater

Publikováno v: Seymour, J F, Kipps, T J, Eichhorst, B F, D'Rozario, J, Owen, C J, Assouline, S, Lamanna, N, Robak, T, de la Serna, J, Jaeger, U, Cartron, G, Montillo, M, Mellink, C, Chyla, B, Panchal, A, Lu, T, Wu, J Q, Jiang, Y, Lefebure, M, Boyer, M & Kater, A P 2022, ' Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab ', Blood, vol. 140, no. 8, pp. 839-850 . https://doi.org/10.1182/blood.2021015014
Blood, 140(8), 839-850. American Society of Hematology

The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia [CLL]; ClinicalTrials.gov identifier #NCT02005471) repor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83c7132b29981ecd44d57ac24adc9bd1
https://research.vumc.nl/en/publications/44bbc898-4d41-4197-810b-c7285b14f884

CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia

Autor: Julia, von Tresckow, Paula, Cramer, Jasmin, Bahlo, Sandra, Robrecht, Petra, Langerbeins, Anna-Maria, Fink, Othman, Al-Sawaf, Thomas, Illmer, Holger, Klaproth, Sven, Estenfelder, Matthias, Ritgen, Kirsten, Fischer, Clemens-Martin, Wendtner, Karl-Anton, Kreuzer, Stephan, Stilgenbauer, Sebastian, Böttcher, Barbara F, Eichhorst, Michael, Hallek

Publikováno v: Leukemia. 33(5)

Obinutuzumab (GA101) and ibrutinib show excellent efficacy for treatment of chronic lymphocytic leukemia (CLL). Preclinical investigations and a complementary safety profile were in support of testing their combined use. The exploratory CLL2-BIG-tria

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b48db68ad011c6a2d31dfa8b85111365
https://pubmed.ncbi.nlm.nih.gov/30568174

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

Autor: Barbara F, Eichhorst, Raymonde, Busch, Stephan, Stilgenbauer, Martina, Stauch, Manuela A, Bergmann, Matthias, Ritgen, Nicole, Kranzhöfer, Robert, Rohrberg, Ulrike, Söling, Oswald, Burkhard, Anne, Westermann, Valentin, Goede, Carmen D, Schweighofer, Kirsten, Fischer, Anna-Maria, Fink, Clemens M, Wendtner, Günter, Brittinger, Hartmut, Döhner, Bertold, Emmerich, Michael, Hallek, M, Sandmann

Publikováno v: Blood. 114:3382-3391

Although chronic lymphocytic leukemia (CLL) is a disease of elderly patients, subjects older than 65 years are heavily underrepresented in clinical trials. The German CLL study group (GCLLSG) initiated a multicenter phase III trial for CLL patients o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea41726bdac5509560f6848c66644f81
https://doi.org/10.1182/blood-2009-02-206185